Study of SHR-A2102 and Adebrelimab for muscle-invasive bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, for people with muscle-invasive bladder cancer that hasn't spread. The goal is to see if this treatment can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have muscle-invasive bladder cancer that hasn't spread to other parts of the body.
- You are generally able to care for yourself (ECOG score 0 or 1) and expected to live at least 2 years.
- You have at least one tumor that can be measured by scans.
- Your major organs (kidneys, liver, heart, etc.) are working well enough.
- You haven't had any other cancer, serious infections, or heart problems recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—SHR-A1921 (a targeted therapy) and Adebrelimab (an immunotherapy)—for people with a specific type of advanced breast cancer (HR-positive, HER2-negative, PD-L1 positive). It aims to see if this combo can help when hormone therapy and chemotherapy haven't worked well enough.
This trial tests two new drugs (SHR-1501 and SHR-2005) given directly into the bladder for people with high-risk bladder cancer that can't be fully removed with standard surgery and who aren't able to have their bladder removed. The goal is to see if this combination can control the cancer and avoid the need for bladder removal.
This study tests a new drug, SHR-2005, given directly into the bladder through a catheter. It is for people with intermediate- or high-risk bladder cancer that hasn't spread into the muscle, and aims to see if it is safe and how well it works.
This trial tests a new drug SHR-A2102 combined with other treatments for advanced or metastatic breast cancer. It aims to see if the combination is safe and effective.
This trial tests a new drug called SHR-A2102, which is a type of targeted therapy (an antibody-drug conjugate) for advanced urothelial carcinoma (bladder cancer). It may help if your cancer has not responded to standard treatments or if you are starting treatment for advanced disease.
This trial tests a new combination of two medications, SHR-A2102 and adebrelimab, for people with advanced bladder cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Muscular Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.